孟买的 Entod Pharmaceuticals 与印度的 DCGI 会面，讨论因索赔问题而暂停其 PresVu 滴眼液的问题。 Mumbai's Entod Pharmaceuticals met with India's DCGI over suspension of their PresVu eye drops due to claims concerns.
孟买的Entod制药公司在PresVu眼滴暂停使用后, 与印度药品总经理(DCGI)会面, Mumbai's Entod Pharmaceuticals met with India's Drug Controller General (DCGI) after the suspension of their PresVu eye drops, approved for presbyopia treatment. 由于担心误导性声明而颁布的暂停令促使首席执行官 Nikkhil K Masurkar 澄清说，这些滴剂只是处方药，不能替代老花镜。 The suspension, enacted due to concerns over misleading claims, prompted CEO Nikkhil K Masurkar to clarify that the drops are prescription-only and not a substitute for reading glasses. Entod承诺遵守管制条件,并寻求重新考虑暂停。 Entod has committed to comply with regulatory conditions and seeks to have the suspension reconsidered.